Valion Bio (VBIO) Share-based Compensation Growth (1y) (2022 - 2026)
Powered by 
Analysis
Valion Bio (VBIO) Share-based Compensation Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.90% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 2.67% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 71.86% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -3.46% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -7.69% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -22.43% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.34% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | -30.42% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -30.42% |
| Dec 31, 2025 | 136.51% |
| Sep 30, 2025 | 512.70% |
| Jun 30, 2025 | 847.54% |
| Mar 31, 2025 | 85.19% |
| Dec 31, 2024 | 8.62% |
| Sep 30, 2024 | 20.83% |
| Jun 30, 2024 | -33.33% |
| Mar 31, 2024 | -35.71% |
| Dec 31, 2023 | -48.21% |
| Sep 30, 2023 | -57.52% |
| Jun 30, 2023 | -27.68% |
| Mar 31, 2023 | -92.01% |
| Dec 31, 2022 | -53.14% |
| Sep 30, 2022 | 391.30% |
| Jun 30, 2022 | 1,300.00% |
| Mar 31, 2022 | 178.79% |